When the Japanese government raised the tax on cigarettes on Oct. 1, it could have started a public health revolution in this land of heavy smokers.
The tax increase should also have been a bonanza for Pfizer, the world’s biggest pharmaceutical company, which makes the leading drug to help smokers break the habit.
Instead, it became a missed opportunity.
Despite ample notice of the change, Pfizer failed to produce enough of the drug, Chantix, which is sold as Champix in Japan. When tens of thousands of would-be quitters rushed to their doctors for prescriptions, Pfizer was overwhelmed.
Less than two weeks after the tax increase went into effect, the company was forced to suspend sales of the drug to new patients until it could ramp up production.
Now, with the drug still difficult to get, Japanese health professionals and many of the nation’s smokers are grumbling.
And Pfizer has given up millions of dollars in potential Chantix sales, at least temporarily, at a time when overseas markets are growing in importance. In the US, prescriptions for the drug plunged after the US Food and Drug Administration (FDA) warned doctors about psychiatric side effects.
“After all that advertising, it turns out they don’t have enough,” said Hiroya Kumamaru, director of the KI Akihabara Clinic in Tokyo, who is turning away patients.
His clinic has enough of the drug for only the 80 patients who began their treatment before the supply squeeze.
“They should have predicted something like this,” he said.
A Pfizer spokesman in Tokyo, Kinji Iwase, said the company misjudged interest in the drug among Japanese smokers.
“An extraordinary number of people decided to quit, and our reading of the situation was off,” Iwase said. “We expected more demand, but not to this extent.”
Japan has long been a smokers’ stronghold. Cheap cigarettes sold by a government-controlled tobacco company and lax anti-smoking laws — smokers have almost total freedom to light up at bars, restaurants and even schools and government offices — have long encouraged the habit. About 130,000 people a year die of tobacco-related illnesses in Japan, according to the WHO.
However, a growing health consciousness, tighter regulations on tobacco advertising and increasingly strict smoking bans on public transport have contributed to a gradual decline in smoking. The smoking rate for men was 36.6 percent last year, 2.3 percentage points lower than a year earlier — though far above the 24 percent smoking rate among men in the US.
The tax increase, prompted by health concerns as well as a need to raise revenue for Japan’s government, was expected to spur an even more sharp and sustained flight from cigarettes. On Oct. 1, the price of a pack of 20 cigarettes jumped from ¥300, or about US$3.60, to more than ¥400, including ¥70 in taxes.
Ahead of the increase, smokers rushed to stock up; tobacco sales surged 88 percent in September from a year earlier, but slumped 70 percent in October, according to the Tobacco Institute of Japan.
Surveys suggest that many smokers in Japan are looking to quit. In one November poll of 1,110 smokers by Rakuten Research, 13.9 percent of respondents said they had stopped smoking, while 15.5 percent said they planned to stop.
While sales of nicotine patches and smoking alternatives have risen, Chantix seems to be the preference for smokers trying to stop.
Introduced in the US in 2006, Chantix, which works by blocking receptors in the brain and suppressing the positive feelings induced by cigarettes, was initially seen as a global blockbuster. However, reports of possible side effects, including aggression and thoughts of suicide, prompted the FDA in 2009 to require the drug to carry the agency’s strongest warning on its packaging. That set off a sharp drop in sales in the US.
Since then, Pfizer has tried to emphasize the benefits of quitting smoking over the risks posed by Chantix, and has stressed that further studies are needed to determine whether the problems are caused by the drug itself or are symptoms of nicotine withdrawal.
To make up for lost revenue at home, Pfizer has also looked increasingly to foreign markets. In the first nine months of last year, while revenue from Chantix in the US fell another 16.8 percent to US$252 million, sales in the rest of the world grew 22.17 percent to US$270 million.
Clearing Japan’s drug-approval process in 2008, Pfizer successfully wooed Japanese doctors to prescribe the drug. Japan’s national health insurance covered 70 percent of the ¥60,000 cost for a recommended 12-week prescription.
To stoke public interest, Pfizer started a major ad campaign, starring the slick Hiroshi Tachi, Japan’s answer to the chain-smoking Don Draper of the US’ Mad Men. Tachi declared that Chantix had helped him quit smoking, and posed in posters with a party horn between his fingers instead of his trademark cigarette. Soon, Japanese blogs raved about the new “almighty” drug that would help Japan kick its cigarette habit. There was little coverage in Japan of Chantix’s potential side effects.
By August, Pfizer was selling the drug to about 70,000 patients a month in Japan. However, that did not prepare the company for the jump in demand related to the tax increase. In September, prescriptions more than doubled to 170,000, and they rose even more in October.
On Oct. 12, Pfizer announced that it was stopping shipments of its “starter packs,” and instructed clinics to stop accepting new patients.
Reiko Ono, 33, who has smoked for more than a decade, was one of the last to secure supplies of Champix at a Tokyo clinic. She has completed eight of the 12 weeks of recommended treatment, and has, until now, resisted the urge to light up.
“It hasn’t been as difficult as I thought,” Ono said.
However, many of Ono’s colleagues who sought the drug were told to wait, she said. “I’m lucky I moved quickly,” she said.
Particularly irritating to many smokers is that Pfizer had almost a year to prepare for a surge in demand; the tax increase was approved in December 2009.
Pfizer is now reassuring would-be customers that they, too, will soon have access to Chantix. This month, the drug maker says, it will have at least 450,000 starter packs available.
Health professionals say that further reductions in smoking-related deaths will hinge on whether the government levies further taxes on cigarettes, which remain cheaper than in the US and Europe, and bucks the influence of Japan Tobacco, still half-owned by the Finance Ministry.
The Democratic Party of Japan, which took power last year, has been more proactive in setting a nonsmoking agenda, and some lawmakers are pressing to do much more.
“This is just the first step. An ideal scenario is to raise tobacco prices to as much as ¥1,000,” a Democratic lawmaker, Yoko Komiyama, said. “Whatever it takes to get more people to quit.”
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
Former president Ma Ying-jeou’s (馬英九) trip to China provides a pertinent reminder of why Taiwanese protested so vociferously against attempts to force through the cross-strait service trade agreement in 2014 and why, since Ma’s presidential election win in 2012, they have not voted in another Chinese Nationalist Party (KMT) candidate. While the nation narrowly avoided tragedy — the treaty would have put Taiwan on the path toward the demobilization of its democracy, which Courtney Donovan Smith wrote about in the Taipei Times in “With the Sunflower movement Taiwan dodged a bullet” — Ma’s political swansong in China, which included fawning dithyrambs